Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam
Epilepsy, Partial
About this trial
This is an interventional treatment trial for Epilepsy, Partial focused on measuring Epilepsy, Partial Onset Seizures, Seletracetam, Levetiracetam
Eligibility Criteria
Inclusion Criteria: Males/Females from 18 to 65 years of age (minimum body weight of 40 kg) Subjects with a confirmed diagnosis of epilepsy suffering from partial onset seizures whether or not secondarily generalized Subjects who have been treated for epilepsy for >= 6 months and are currently uncontrolled while being treated with 1-3 concomitant AED(s), inclusive of levetiracetam (LEV) Female subjects without childbearing potential or those who are using an acceptable contraceptive method Exclusion Criteria: Seizures occurring in clusters. Status epilepticus within 6 months of Visit 1. History of non-epileptic seizures Subjects on vigabatrin Subjects on felbamate, unless treatment has been continuous for >2 years Ongoing psychiatric disease other than mild controlled disorders Subjects with clinically significant organ dysfunction Known allergic reaction or intolerance to pyrrolidine derivatives and/or excipients Pregnant or lactating women Use of benzodiazepines (for any indication) taken at a higher frequency than an average of once a week, unless counted as one of the concomitant Antiepileptic Drug (AEDs).
Sites / Locations
Arms of the Study
Arm 1
Experimental
Seletracetam
Escalating doses twice daily were to be administered.